Rydar Equities’s AbCellera Biologics ABCL Stock Holding History

Rydar Equities’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.57K	Buy	+200	New	+$1.9K	﹤0.01%	387

Other funds holding ABCL

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

GAA

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

DWM

DKM Wealth Management Stockton, California $158M AUM 11.62% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Pacifica Partners Surrey, Canada $332M AUM 43.09% 1-Year Est. Return

CIA

Cape Investment Advisory Mcdonough, Georgia $388M AUM 17.15% 1-Year Est. Return

Rydar Equities's ABCL Position: Q3 2026 in Review

Rydar Equities opened a new position in AbCellera Biologics (ABCL) in Q3 2026: 200 shares worth $2.57K. The stake represents ﹤0.01% of the portfolio and ranks #387 among its holdings.

8 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.

Rydar Equities held 200 shares of AbCellera Biologics worth $2.57K as of Q3 2026.
AbCellera Biologics was a new Rydar Equities position in Q3 2026.
AbCellera Biologics made up ﹤0.01% of Rydar Equities's portfolio in Q3 2026, its #387 holding.
8 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.

Based on Rydar Equities's 13F filing for Q3 2026, filed 13 Oct 2026.